Drew MD - Jounce Therapeutics Founder
| JNCEDelisted Stock | USD 1.88 0.00 0.00% |
Insider
Drew MD is Founder of Jounce Therapeutics
| Phone | 857 259 3840 |
| Web | https://jouncetx.com |
Jounce Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.1404) % which means that it has lost $0.1404 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2503) %, meaning that it created substantial loss on money invested by shareholders. Jounce Therapeutics' management efficiency ratios could be used to measure how well Jounce Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 11.89 M in liabilities with Debt to Equity (D/E) ratio of 0.08, which may suggest the company is not taking enough advantage from borrowing. Jounce Therapeutics has a current ratio of 6.64, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Jounce Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Jounce Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Jounce Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Jounce to invest in growth at high rates of return. When we think about Jounce Therapeutics' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| MD FACP | NextCure | 71 | |
| Karl MD | Achilles Therapeutics PLC | 57 | |
| Lieping MD | NextCure | 66 | |
| MHROD SHRMSCP | Assembly Biosciences | N/A | |
| Kim Blickenstaff | Nuvation Bio | 68 | |
| Sergey Yurasov | Nuvation Bio | 51 | |
| MBA MD | Spero Therapeutics | 43 | |
| Michele Anderson | Assembly Biosciences | N/A | |
| Tharaknath Rao | Assembly Biosciences | N/A | |
| Dr IV | Assembly Biosciences | 52 | |
| Michael MSBA | NextCure | 63 | |
| Gary Hattersley | Nuvation Bio | 57 | |
| Adam Zlotnick | Assembly Biosciences | N/A | |
| W Vernon | Nuvation Bio | 65 | |
| BSc FRCPath | Achilles Therapeutics PLC | 59 | |
| MBA BS | CytomX Therapeutics | 45 | |
| Ian Critchley | Spero Therapeutics | N/A | |
| Uri MD | Assembly Biosciences | 52 | |
| AO FRACP | Assembly Biosciences | 65 | |
| Angela MD | Spero Therapeutics | N/A | |
| James Brady | Spero Therapeutics | N/A | |
Management Performance
| Return On Equity | -0.25 | |||
| Return On Asset | -0.14 |
Jounce Therapeutics Leadership Team
Elected by the shareholders, the Jounce Therapeutics' board of directors comprises two types of representatives: Jounce Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Jounce. The board's role is to monitor Jounce Therapeutics' management team and ensure that shareholders' interests are well served. Jounce Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Jounce Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| CPA CPA, CFO Treasurer | ||
| Drew MD, Founder | ||
| Barbara Duncan, Independent Director | ||
| Luis Diaz, Director | ||
| Robert Schreiber, Founder | ||
| Padmanee MD, Founder | ||
| Drew Pardoll, Co-Founder | ||
| Louis MD, Founder | ||
| Deborah Law, Chief Scientific Officer | ||
| Elizabeth MD, Chief Officer | ||
| Richard Murray, President CEO, Director | ||
| Kimberlee Drapkin, CFO, Treasurer | ||
| Robert Kamen, Independent Director | ||
| Hugh Cole, Chief Business Officer and Head of Corporate Development | ||
| Thomas Gajewski, Co-Founder | ||
| Elizabeth Trehu, Chief Medical Officer | ||
| Robert Tepper, Independent Director | ||
| Perry Karsen, Chairman of the Board | ||
| Padmanee Sharma, Co-Founder | ||
| Cary Pfeffer, Independent Director | ||
| Duncan Higgons, Independent Director | ||
| James Allison, Co-Founder |
Jounce Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Jounce Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.25 | |||
| Return On Asset | -0.14 | |||
| Profit Margin | (0.62) % | |||
| Operating Margin | (0.64) % | |||
| Current Valuation | (82.09 M) | |||
| Shares Outstanding | 52.64 M | |||
| Shares Owned By Insiders | 15.99 % | |||
| Shares Owned By Institutions | 85.33 % | |||
| Number Of Shares Shorted | 2.02 M | |||
| Price To Earning | 10.76 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. Note that the Jounce Therapeutics information on this page should be used as a complementary analysis to other Jounce Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Other Consideration for investing in Jounce Stock
If you are still planning to invest in Jounce Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Jounce Therapeutics' history and understand the potential risks before investing.
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |